Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem J. 2006 Jun 1;396(2):235-42.

Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.

Author information

1
Developmental Therapeutics Program, DCTD (Division of Cancer Treatment and Diagnosis), NCI (National Cancer Institute), Bethesda, MD 20892, USA.

Abstract

Tubulysin A (tubA) is a natural product isolated from a strain of myxobacteria that has been shown to depolymerize microtubules and induce mitotic arrest. The potential of tubA as an anticancer and antiangiogenic agent is explored in the present study. tubA shows potent antiproliferative activity in a panel of human cancer cell lines irrespective of their multidrug resistance properties. It induces apoptosis in cancer cells but not in normal cells and shows significant potential antiangiogenic properties in several in vitro assays. It is efficacious in initial animal studies using a hollow fibre assay with 12 different human tumour cell lines. This study suggests that both in vitro and preclinical profiles of tubA may translate into clinically useful anticancer properties.

PMID:
16489930
PMCID:
PMC1462728
DOI:
10.1042/BJ20051735
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center